Patent US12594280B2: Antiviral Compositions for Influenza Treatment
Summary
USPTO granted Patent US12594280B2 to Universite Claude Bernard Lyon 1 covering antiviral pharmaceutical compositions containing Etilefrine and Diltiazem for preventing and treating influenza virus infections. The patent includes 10 claims and covers the use of these compounds in veterinary and pharmaceutical compositions.
What changed
USPTO issued Patent US12594280B2 to Universite Claude Bernard Lyon 1, granting exclusive rights to antiviral compositions comprising Etilefrine and Diltiazem for influenza treatment. The patent, classified under CPC codes A61P 31/16 and A61P 31/12, covers both pharmaceutical and veterinary applications. The filing date was May 31, 2022, with application number 17828245.
For pharmaceutical companies and biotech firms developing flu treatments, this patent establishes intellectual property barriers around Etilefrine and Diltiazem as antiviral agents. Companies pursuing similar therapeutic approaches should conduct freedom-to-operate analyses to avoid potential infringement exposure. Research institutions may explore licensing opportunities for developing these compositions into commercial therapeutic products.
What to do next
- Monitor patent portfolio for potential licensing opportunities
- Review composition claims for freedom-to-operate analysis
- Assess applicability to flu treatment product development pipelines
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Antiviral compositions for treating the flu
Grant US12594280B2 Kind: B2 Apr 07, 2026
Assignee
UNIVERSITE CLAUDE BERNARD LYON 1
Inventors
Manuel Rosa-Calatrava, Olivier Terrier, Julien Textoris, Guy Boivin, Mario Pizzorno
Abstract
The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.
CPC Classifications
A61K 31/554 A61K 31/5383 A61K 31/506 A61K 31/53 A61P 31/16 A61P 31/12
Filing Date
2022-05-31
Application No.
17828245
Claims
10
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Grants - Therapeutics (A61P) publishes new changes.